Evidence map›Paper›PMID 32656265›Full record

ReviewJournal of diabetes research2020

The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus.

Thiquynhnga Nguyen, Min Gong, Song Wen, Xinlu Yuan, Chaoxun Wang, Jianlan Jin, Ligang Zhou

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Thiquynhnga NguyenDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.
Min GongDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.
Song WenDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.
Xinlu YuanDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.
Chaoxun WangDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.ORCID https://orcid.org/0000-0002-3237-3405
Jianlan JinDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.
Ligang ZhouDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.ORCID https://orcid.org/0000-0003-4824-0735
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incretin-based therapy is now a prevalent treatment option for patients with type 2 diabetes mellitus (T2DM). It has been associated with considerably good results in the management of hyperglycemia with cardiac or nephron-benefits. For this reason, it is recommended for individuals with cardiovascular diseases in many clinical guidelines. As an incretin hormone, glucagon-like peptide-1 (GLP-1) possesses multiple metabolic benefits such as optimizing energy usage, maintaining body weight,

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1HumansHypoglycemic AgentsInsulin-Secreting CellsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1Hypoglycemic Agents

Identifiers

PMID32656265
PMCPMC7320283
OpenAlexW3036660594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.